Dupixent® (dupilumab) is the First Biologic to Significantly Reduce Itch and Skin Lesions in Phase 3 Trial for Prurigo Nodularis, Demonstrating the Role of Type 2 Inflammation in this Disease

TARRYTOWN, N.Y. and PARIS, Oct. 22, 2021 /PRNewswire/ -- Pivotal trial met primary and all key secondary endpoints Dupixent significantly reduced itch at 12 weeks, and nearly three times as many Dupixent patients experienced reductions in both itch and skin lesions at 24 weeks Prurigo...

from PR Newswire: https://ift.tt/3pr6riU